The company’s co-founder will discuss the use of artificial intelligence and machine learning applications for precision medicine in neurology
BOSTON, 24 January 2023 /PRNewswire/ — Beacon Biosignals CEO and Co-Founder Jacob DonoghueMD, Ph.D., will speak at the Precision Medicine World Conference (PMWC) 2023, held in Silicon Valley from 25.-27. Januarythe company announced today.
PMWC is the premier precision medicine conference, bringing together more than 2,500 recognized leaders, top global researchers, medical professionals and innovators in an effort to accelerate the development and spread of precision medicine. It provides a forum for the exchange of information on the latest advances in technology, clinical implementation, research and in all aspects related to the regulatory and reimbursement sector.
Dr. Donoghue will be part of a panel session titled “AI/ML Applications for Patient Outcomes Prediction and Clinical Support” at Friday, January 27from 1 to 2 p.m by Santa Clara Congress Center i Santa Clara, California. This session is part of Track 2 (AI & Data Sciences in Drug Discovery & Clinical Research) on Day 3 of the Annual Conference.
The panel will be moderated by Alex Shermanchief employee in neurology at Harvard Medical School and director of the Center for Innovation and Bioinformatics at the Neurological Clinical Research Institute at Massachusetts General Hospital (MGH). In addition to Dr. Donoghue includes confirmed panelists:
- Indu NavarAltALS
- Nuray Yurt, Novartis Oncology
- Marie Abele Bind, MGH/Harvard Medical School
Dr. Donoghue completed his medical degree from the Health Sciences & Technology program at Harvard Medical School and his Ph.D. in neuroscience from WITH, where his research focused on computational neurophysiology and the effects of neuroactive compounds on brain network activity. He co-founded Beacon Biosignals in 2019.
Dr. Donoghue will discuss Beacon’s progress using machine learning to analyze epileptiform burden and sleep endpoints derived from electroencephalogram (EEG) recordings. Stratifying patients based on these insights provides a more detailed understanding of a patient’s condition and can lead to more targeted and effective treatment plans.
The world’s leading computational neurodiagnostics company, Beacon, leverages machine learning to unlock the power of EEG data to advance precision medicine for neurological and psychiatric disorders.
About Beacon Biosignals
Beacon’s machine learning platform for EEG enables and accelerates new treatments that transform the lives of patients with neurological, psychiatric or sleep disorders. Through new machine learning algorithms, large clinical datasets and advances in software development, Beacon Biosignals provides biopharma companies with unparalleled tools for efficacy monitoring, patient stratification and clinical trial endpoints from brain data. For more information, visit https://beacon.bio/. For careers, visit https://beacon.bio/careers; for partnership inquiries, visit https://beacon.bio/contact. Follow us on Twitter (@Biosignals) or LinkedIn (https://www.linkedin.com/company/beacon-biosignals).
Amendola Communications for Beacon Biosignals
SOURCE Beacon Biosignals